Aldeyra Therapeutics has been granted a patent for a method of treating retinitis pigmentosa using an intravitreal composition of methotrexate, sucrose, and phosphate buffer. The composition reduces secondary punctate keratitis incidence by 10-50% compared to non-GMP methotrexate. GlobalData’s report on Aldeyra Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Aldeyra Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Aldeyra Therapeutics's grant share as of February 2024 was 24%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of retinitis pigmentosa with methotrexate eye injections
A recently granted patent (Publication Number: US11911385B1) discloses a method for treating retinitis pigmentosa (RP) by administering a specific composition intravitreally to a subject in need. The composition includes methotrexate at a concentration ranging from about 5 mg/mL to about 12 mg/mL, sucrose at a concentration of about 7% w/v to about 12% w/v, and a phosphate buffer. The volume of the composition administered is crucial, ranging from about 20 µL to about 300 µL, with a specific reduction in the incidence of secondary punctate keratitis by about 10% to 50% compared to subjects receiving other compositions of methotrexate.
Furthermore, the method outlined in the patent claims significant reductions in secondary punctate keratitis incidence, ranging from about 20% to 40% to as high as 40% compared to subjects administered non-GMP compositions of methotrexate. The method also demonstrates statistically significant reductions in punctate keratitis across a representative group of subjects, emphasizing the efficacy of the composition. Additionally, the patent details specific concentrations of methotrexate, sucrose, and phosphate buffer, along with the transit rate of the composition in silicone oil, providing a comprehensive guide for administering the treatment. The method also considers the subject's medical history, dose variations, and frequency of administration to optimize the treatment for RP.
To know more about GlobalData’s detailed insights on Aldeyra Therapeutics, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
